Informations générales (source: ClinicalTrials.gov)
Long Term Brain Toxicity of Chemotherapy in Patients Treated for a Bone TumorDuring Childhood or Adolescence
Interventional
N/A
Gustave Roussy, Cancer Campus, Grand Paris (Voir sur ClinicalTrials)
mars 2021
avril 2025
13 septembre 2025
To assess the neurocognitive outcomes in patients treated with chemotherapy for a
malignant bone tumor during childhood and adolescence and the factors associated with
neurocognitive impairment and/or complaints
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Brice Fresneau, Dr | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
For study OSE A and B
- Patients treated for a bone sarcoma: Ewing or osteosarcoma
- Age under 19 years at initial diagnosis
- Treated in the Pediatric Oncology Department of Gustave
For patients diagnosed between 01.01.2001 and 31.12.2010: patients alive in complete
remission at least 5 years after diagnosis
- Treated with at least one course of HDMTX for osteosarcoma
- Treated without HDMTX for Ewing sarcoma
- Time interval between the end of treatment and inclusion >10 y
- Age > 21 y at inclusion
- Patients with informed consent signed
- Patient under guardianship
- Affiliated to French health insurance or beneficiary of the same or equivalent
For study OSE- B only:
- Treated with at least 8 courses of HDMTX for osteosarcoma
- Treated without HDMTX for Ewing sarcoma
- Patients with Ewing sarcoma will have to be matched with osteosarcoma patients
according to age at the time of treatment, sex, and duration of follow-up
- School level equivalent of at least the end of primary school
For study OSE A and B
- Patients treated for a bone sarcoma: Ewing or osteosarcoma
- Age under 19 years at initial diagnosis
- Treated in the Pediatric Oncology Department of Gustave
For patients diagnosed between 01.01.2001 and 31.12.2010: patients alive in complete
remission at least 5 years after diagnosis
- Treated with at least one course of HDMTX for osteosarcoma
- Treated without HDMTX for Ewing sarcoma
- Time interval between the end of treatment and inclusion >10 y
- Age > 21 y at inclusion
- Patients with informed consent signed
- Patient under guardianship
- Affiliated to French health insurance or beneficiary of the same or equivalent
For study OSE- B only:
- Treated with at least 8 courses of HDMTX for osteosarcoma
- Treated without HDMTX for Ewing sarcoma
- Patients with Ewing sarcoma will have to be matched with osteosarcoma patients
according to age at the time of treatment, sex, and duration of follow-up
- School level equivalent of at least the end of primary school
For study OSE A and B
- Brain radiotherapy
- Previous relapse except those treated by local treatment without any chemotherapy
- Second malignancy treated with chemotherapy
- High dose chemotherapy with stem cell support
- Non-French speaking patients
- Pregnant and breastfeeding women
For study OSE- B only:
- Patient deprived of his liberty by a judicial or administrative decision